Financial News Feed

Stronger Sell Today XLRN ranks #4720 as SELL CANDIDATE #4720 Weaker Sell

Acceleron Pharma Inc. stock forecast

XLRN stock forecast

The Investment Thesis On Acceleron Pharma
11:22pm, Monday, 27'th May 2019
No summary available....

Read more

XLRN earnings call for the period ending March 31, 2019....

Read more

Acceleron Pharma, Inc. (NASDAQ:XLRN) Q1 2019 Earnings Conference Call May 9, 2019, 5:00 pm ET Company Participants Todd James - VP, IR & Corporate Communica...

Read more

No summary available....

Read more

No summary available....

Read more

Acceleron Pharma Q1 2019 Earnings Preview
09:35pm, Wednesday, 08'th May 2019
No summary available....

Read more

No summary available....

Read more

No summary available....

Read more

No summary available....

Read more

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news....

Read more

No summary available....

Read more

No summary available....

Read more

Both Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) and Acceleron Pharma Inc. (NASDAQ:XLRN) are each other’s competitor in the Biotechnology industry. Thus the contrast of their risk, analyst recommend...

Read more

We will be comparing the differences between Acceleron Pharma Inc. (NASDAQ:XLRN) and Protagonist Therapeutics Inc. (NASDAQ:PTGX) as far as analyst...

Read more

Artal Group Sa decreased its stake in Acceleron Pharma Inc (Call) (XLRN) by 80% based on its latest 2018Q4 regulatory filing with the SEC. Artal Group Sa sold 800,000 shares as the company’s stock d...

Read more

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank